Format

Send to

Choose Destination
See comment in PubMed Commons below
Expert Rev Anti Infect Ther. 2010 Apr;8(4):397-404. doi: 10.1586/eri.10.16.

Antifungal prophylaxis and treatment in patients with hematological malignancies.

Author information

1
Department of Medicine, Queen Mary Hospital, University of Hong Kong, Hong Kong. ghwang@graduate.hku.hk

Abstract

Invasive fungal infection (IFI) is a serious and common complication in hematological patients. The risk is highest among acute leukemia patients undergoing induction chemotherapy and patients undergoing allogeneic hematopoietic stem-cell transplantation. Owing to the difficulty in diagnosing IFIs and the fatality rate associated with delayed treatment, antifungal prophylaxis and empirical antifungal therapy are standard management approaches. Novel agents, such as posaconazole and echinocandins, broaden our armamentarium against IFIs and improve patients' outcomes.

PMID:
20377335
DOI:
10.1586/eri.10.16
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Taylor & Francis
    Loading ...
    Support Center